Psychiatry · New York, NY
NPI
1063726966
Since 2010
Specialty
Psychiatry
Code 2084P0800X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
1049 Park Ave, Unit 1b
New York, NY, 10028
Phone (212) 289-2299
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$3.7M
7,381 prescriptions
Company payments, 2025
$316K
From 10 companies
Medicare prescription drug claims, 2024
In 2024, the drug Manish Zinzuvadia prescribed most often to Medicare patients was Olanzapine, with 639 prescriptions and refills. In total Manish Zinzuvadia wrote 7,381 Medicare prescriptions that cost $3.7M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-03-07.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Olanzapine Generic | 639 | 651 | 50 | $73K |
| Risperidone Generic | 571 | 575 | 48 | $51K |
| Quetiapine Fumarate Generic | 485 | 496 | 30 | $54K |
| Clonazepam Generic | 363 | 363 | 33 | $9,575 |
| Uzedy Risperidone | 320 | 334 | 34 | $1.1M |
| Divalproex Sodium Generic | 274 | 274 | 26 | $39K |
| Lorazepam Generic | 253 | 253 | 21 | $10K |
| Sertraline Hcl Generic | 251 | 251 | 21 | $6,744 |
| Divalproex Sodium Er Divalproex Sodium | 235 | 235 | 18 | $36K |
| Buspirone Hcl Generic | 209 | 209 | 20 | $11K |
| Benztropine Mesylate Generic | 206 | 208 | 21 | $4,387 |
| Fluvoxamine Maleate Generic | 205 | 205 | 13 | $18K |
| Aripiprazole Generic | 202 | 206 | 18 | $31K |
| Escitalopram Oxalate Generic | 190 | 198 | 20 | $7,337 |
| Citalopram Hbr Citalopram Hydrobromide | 155 | 155 | 12 | $2,849 |
Brand drugs: 1,161 claims; generic drugs: 6,220 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Manish Zinzuvadia $316K ($316K in general payments such as food, travel and fees) from 10 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $112K.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 106 | $112K |
| Teva Pharmaceuticals USA, Inc. TEVA | 53 | $60K |
| Otsuka America Pharmaceutical, Inc. 4578.T | 44 | $56K |
| Alkermes, Inc. ALKS | 73 | $46K |
| Axsome Therapeutics, Inc. AXSM | 24 | $17K |
| Luye Pharma (USA) Ltd. 2186.HK | 15 | $15K |
| Abbvie Inc. ABBV | 20 | $6,382 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. 4578.T | 2 | $2,053 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 4 | $474 |
| Lundbeck LLC | 10 | $210 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.